# FDA removes suicide warning for obesity drug class, approves pill, requests heart safety study. - Date: 2026-04-14 - Category: Biotech & Life Sciences The FDA approved Lillys obesity pill in 50 days, fastest new drug in 24 years, then demanded CV safety trials. Six weeks earlier it cleared the GLP-1 class of suicide risk. Those two calls weeks apart show an agency still figuring out what standard obesity drugs should meet. ---